Retatrutide
Metabolic / Triple Incretin Agonist
Phase 3 (obesity, T2D); not yet approved
GLP-1 AgonistGIP AgonistGlucagon AgonistWeight ManagementMetabolicPhase 3
Retatrutide is a first-in-class triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. By adding glucagon receptor activity to the dual incretin mechanism of tirz…
Full Retatrutide profile →
Cagrilintide
Metabolic / Amylin Analog
Phase 3 (obesity); not yet approved
Amylin AnalogWeight ManagementMetabolicPhase 3Combination Therapy
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk that acts on amylin receptors (calcitonin receptor/RAMP complex) in the hypothalamus and brainstem to regulate food intake and body weight. As a compl…
Full Cagrilintide profile →
Stack Compatibility & Key Differences
Both are active research compounds. See individual pages for full protocol data.
Frequently Asked Questions
What is the difference between Retatrutide and Cagrilintide?
Retatrutide: Retatrutide is a first-in-class triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. By adding glucagon receptor activity to the dual incretin mechanism of tirz… Cagrilintide: Cagrilintide is a long-acting amylin analog developed by Novo Nordisk that acts on amylin receptors (calcitonin receptor/RAMP complex) in the hypothalamus and brainstem to regulate food intake and body weight. As a compl…
Can you stack Retatrutide and Cagrilintide?
Both are active research compounds. See individual pages for full protocol data.
Which has a longer half-life, Retatrutide or Cagrilintide?
Retatrutide half-life: ~6 days. Cagrilintide half-life: ~7 days.